Literature DB >> 28435131

Repression of acetaminophen-induced hepatotoxicity by a combination of celastrol and brilliant blue G.

Heba A Abdelaziz1, Mohamed E Shaker2, Mohamed F Hamed3, Nariman M Gameil4.   

Abstract

The sterile inflammatory response is an eminent contributor to acetaminophen (APAP)-hepatotoxicity in humans. Recent advances unraveled an axial role of the NLRP3-inflammasome in APAP-post injury inflammation. Nevertheless, the role of signaling events preceded the NLRP3-inflammasome activation, like the transcription factor NF-κB and the purinergic receptor P2X7, is still unclear and needs further elucidation. Here, we investigated the pharmacological inhibition of these upstream signaling molecules by celastrol and brilliant blue G (BBG) (separately or simultaneously) in APAP-hepatotoxicity in mice. The results indicated that both celastrol and BBG pretreatments, especially when combined together, curbed APAP-induced hepatocellular injury (ALT, AST and LDH) and death (necrosis and apoptosis). The underlying mechanisms of protection of such combination against APAP-challenge were attributed to their efficient cooperation in: i) preventing the consumption of hepatic antioxidants (reduced glutathione and superoxide dismutase); ii) limiting the overproduction of lipid peroxidation aldehydes (malondialdehyde and 4-hydroxynonenal) and total nitrate/nitrite products; iii) attenuating the inflammatory cells accumulation in the liver, as evidenced by reducing the number of F4/80 positive cells/field in immunostaining and myeloperoxidase activity; iv) reversing the dysregulation in production of pro-inflammatory (TNF-α, IL-17A and IL-23) and anti-inflammatory (IL-10) cytokines; and v) enhancing the reparative capacity of injured hepatocytes, as demonstrated by increasing the percentage of PCNA positive hepatocytes per field of immunostaining. In conclusion, this murine study elicits a potential clinical applicability and therapeutic utility of celastrol and BBG combination in human cases of APAP-overdose hepatotoxicity.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Liver inflammation; NF-κB; NLRP3; P2X7

Mesh:

Substances:

Year:  2017        PMID: 28435131     DOI: 10.1016/j.toxlet.2017.04.012

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  9 in total

1.  Celastrol ameliorates acute liver injury through modulation of PPARα.

Authors:  Qi Zhao; Ping Tang; Ting Zhang; Jian-Feng Huang; Xue-Rong Xiao; Wei-Feng Zhu; Frank J Gonzalez; Fei Li
Journal:  Biochem Pharmacol       Date:  2020-05-26       Impact factor: 5.858

2.  P2X7R: pivotal player in sepsis-induced liver damage.

Authors:  Marta Vuerich
Journal:  Purinergic Signal       Date:  2021-01-18       Impact factor: 3.765

Review 3.  Purinergic signaling in hepatic disease.

Authors:  E Velázquez-Miranda; M Díaz-Muñoz; F G Vázquez-Cuevas
Journal:  Purinergic Signal       Date:  2019-10-01       Impact factor: 3.765

4.  Transferrin-functionalised microemulsion co-delivery of β-elemene and celastrol for enhanced anti-lung cancer treatment and reduced systemic toxicity.

Authors:  Qian Zhang; Xin Tian; Xiufeng Cao
Journal:  Drug Deliv Transl Res       Date:  2019-06       Impact factor: 4.617

5.  P2X7 receptor deletion attenuates oxidative stress and liver damage in sepsis.

Authors:  Robson Coutinho-Silva; Luiz Eduardo Baggio Savio; Maria Luciana Larrouyet-Sarto; Augusto Shuiti Tamura; Vinícius Santos Alves; Patrícia T Santana; Roberta Ciarlini-Magalhães; Thuany Prado Rangel; Cassiana Siebert; Josiane R Hartwig; Tiago Marcon Dos Santos; Angela T S Wyse; Christina Maeda Takiya
Journal:  Purinergic Signal       Date:  2020-10-22       Impact factor: 3.765

Review 6.  The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?

Authors:  Luiz E B Savio; Paola de Andrade Mello; Cleide Gonçalves da Silva; Robson Coutinho-Silva
Journal:  Front Pharmacol       Date:  2018-02-06       Impact factor: 5.810

7.  Inhibition of P2X7 Purinergic Receptor Ameliorates Cardiac Fibrosis by Suppressing NLRP3/IL-1β Pathway.

Authors:  Junteng Zhou; Geer Tian; Yue Quan; Junli Li; Xiaojiao Wang; Wenchao Wu; Miaoling Li; Xiaojing Liu
Journal:  Oxid Med Cell Longev       Date:  2020-05-21       Impact factor: 6.543

8.  Colon Targeting of Naringin for Enhanced Cytoprotection Against Indomethacin-Induced Colitis in Rabbits.

Authors:  Eman Ebrahim El Naggar; Elham Abdelmonem Mohamed; Thanaa Mohamed Borg; Ahmed Ramadan El-Sheakh; Mohammed Fawzy Hamed
Journal:  Drug Des Devel Ther       Date:  2020-02-19       Impact factor: 4.162

Review 9.  Celastrol: An Update on Its Hepatoprotective Properties and the Linked Molecular Mechanisms.

Authors:  Mengzhen Li; Faren Xie; Lu Wang; Guoxue Zhu; Lian-Wen Qi; Shujun Jiang
Journal:  Front Pharmacol       Date:  2022-04-04       Impact factor: 5.988

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.